Melphalan (Alkeran, Evomela)
Other Medications · Approved since 1964
Description
Melphalan is a nitrogen mustard alkylating chemotherapy agent used in colorectal cancer through isolated hepatic perfusion (IHP) for patients with unresectable liver metastases. This specialized technique delivers high concentrations of melphalan directly to the liver while minimizing systemic exposure, making it a regional therapy option for liver-confined metastatic disease. The drug is primarily established for treating multiple myeloma and ovarian cancer, but has been adapted for hepatic perfusion in select CRC patients with liver-only or liver-predominant metastases.
Mechanism of Action
Melphalan functions as a bifunctional alkylating agent that cross-links DNA strands by forming covalent bonds with nucleophilic sites, particularly guanine residues. This DNA cross-linking prevents DNA replication and transcription, ultimately leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Alkeran, Evomela |
| Category | Other Medications |
 Status | Off-label |
 EMA Status | EMA Approved |
 Spain Access | Hospital use off-label in CRC |
| Administration | IV |
| Year Approved | 1964 |
| Clinical Trials | 7 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.